JP2005516044A - モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法 - Google Patents

モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法 Download PDF

Info

Publication number
JP2005516044A
JP2005516044A JP2003563468A JP2003563468A JP2005516044A JP 2005516044 A JP2005516044 A JP 2005516044A JP 2003563468 A JP2003563468 A JP 2003563468A JP 2003563468 A JP2003563468 A JP 2003563468A JP 2005516044 A JP2005516044 A JP 2005516044A
Authority
JP
Japan
Prior art keywords
monoclonal antibody
staphylococcal
composition
mab
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003563468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516044A5 (https=
Inventor
コカイ−クン，ジョン，エフ．
モンド，ジェームズ，ジェイ．
フィシャー，ジェラルド，ダブリュー．
スティンソン，ジェフリー，アール．
ウォルシュ，スコット，エム．
リーズ，アンドリュー
Original Assignee
バイオシネクサス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオシネクサス インコーポレーテッド filed Critical バイオシネクサス インコーポレーテッド
Publication of JP2005516044A publication Critical patent/JP2005516044A/ja
Publication of JP2005516044A5 publication Critical patent/JP2005516044A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1296—Gram-positive bacteria from Listeria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2003563468A 2001-12-21 2002-12-23 モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法 Pending JP2005516044A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34180601P 2001-12-21 2001-12-21
PCT/US2002/040925 WO2003063772A2 (en) 2001-12-21 2002-12-23 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies

Publications (2)

Publication Number Publication Date
JP2005516044A true JP2005516044A (ja) 2005-06-02
JP2005516044A5 JP2005516044A5 (https=) 2006-03-02

Family

ID=27662943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003563468A Pending JP2005516044A (ja) 2001-12-21 2002-12-23 モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法

Country Status (5)

Country Link
US (1) US20030224000A1 (https=)
EP (1) EP1465926A4 (https=)
JP (1) JP2005516044A (https=)
CA (1) CA2469571A1 (https=)
WO (1) WO2003063772A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539360A (ja) * 2006-06-06 2009-11-19 クルセル ホランド ベー ヴェー ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
JP2012513414A (ja) * 2008-12-23 2012-06-14 ジェネンテック， インコーポレイテッド プロテインａに対する結合が変化した免疫グロブリン変異体
JP2022173489A (ja) * 2009-06-26 2022-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20050050659A1 (en) 2003-09-09 2005-03-10 The Procter & Gamble Company Electric toothbrush comprising an electrically powered element
WO2005072778A2 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
WO2007024852A2 (en) * 2005-08-22 2007-03-01 Biosynexus Incorporated Methods for testing vaccine candidates against bacterial infection in rodents
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009137677A2 (en) * 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
US20100260752A1 (en) * 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
WO2011017791A1 (pt) * 2009-08-10 2011-02-17 Fundação Oswaldo Cruz Anticorpos monoclonais para a proteína pbp2-a e sequências homólogas para o tratamento de infeçcões e imunodiagnóstico em bactérias do filo firmicutes
WO2011035158A2 (en) 2009-09-17 2011-03-24 Guthery B Eugene Nasal, wound and skin formulations and methods for control of antibiotic-resistant staphylococci and other gram-positive bacteria
MX2012006961A (es) 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
DK2560738T3 (da) 2010-04-23 2019-08-26 Serum Inst India Ltd Simpel fremgangsmåde til samtidig fjernelse af flere urenheder fra dyrkningssupernatanter til ultralave niveauer
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
US9434977B2 (en) * 2013-02-27 2016-09-06 Avent, Inc. Rapid identification of organisms in bodily fluids
WO2014142117A1 (ja) 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
BR112021005522A2 (pt) * 2018-11-21 2021-06-29 Regeneron Pharmaceuticals, Inc. anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, métodos de prevenção, tratamento ou melhoria de infecção por s. aureus, uma condição causada por infecção por s. aureus, ou pelo menos um sintoma de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, uma condição causada por infecção por s. aureus, de pelo menos um sintoma de infecção por s. aureus, para prevenir uma infecção por s. aureus, de prevenção, tratamento ou melhoria de infecção por s. aureus, ou de diminuir a frequência ou gravidade de infecção por s. aureus, em um indivíduo com um cateter, uma articulação protética ou qualquer outro objeto estranho, para prevenir, tratar ou melhorar a infecção estafilocócica, ou para diminuir a frequência ou gravidade da infecção estafilócica
US11440952B2 (en) 2020-10-16 2022-09-13 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
US20220280679A1 (en) * 2021-03-08 2022-09-08 Innovation Chemical and Enviromental Technologies, Inc. Prophylactic Gel Compositions and Use as Barriers to Bacterial and Viral Colonization
WO2023201306A1 (en) * 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508004A (ja) * 1994-08-20 1998-08-04 ダンバイオシスト ユーケー リミテッド 限定されたｚ電位を有するキトサンまたはその誘導体を含む薬剤移送組成物
WO1998057994A2 (en) * 1997-06-16 1998-12-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5681565A (en) * 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JP2003503015A (ja) * 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508004A (ja) * 1994-08-20 1998-08-04 ダンバイオシスト ユーケー リミテッド 限定されたｚ電位を有するキトサンまたはその誘導体を含む薬剤移送組成物
WO1998057994A2 (en) * 1997-06-16 1998-12-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MERKUS,F.W. ET AL: "Cyclodextrins in nasal drug delivery", ADV DRUG DELIV REV, vol. 36, no. 1, JPN7009001074, 1999, pages 41 - 57, XP001023913, ISSN: 0001262654, DOI: 10.1016/S0169-409X(98)00054-4 *
TAKENAGA,M. ET AL: "Microparticle resins as a potential nasal drug delivery system for insulin", J CONTROL RELEASE, vol. Vol.52, No.1-2, JPN7009001075, 1998, pages 81 - 7, XP055552549, ISSN: 0001262655, DOI: 10.1016/S0168-3659(97)00193-4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539360A (ja) * 2006-06-06 2009-11-19 クルセル ホランド ベー ヴェー ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
JP2012513414A (ja) * 2008-12-23 2012-06-14 ジェネンテック， インコーポレイテッド プロテインａに対する結合が変化した免疫グロブリン変異体
JP2022173489A (ja) * 2009-06-26 2022-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体

Also Published As

Publication number Publication date
EP1465926A2 (en) 2004-10-13
WO2003063772A2 (en) 2003-08-07
CA2469571A1 (en) 2003-08-07
US20030224000A1 (en) 2003-12-04
EP1465926A4 (en) 2006-02-08
WO2003063772A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
JP2005516044A (ja) モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法
JP6317670B2 (ja) ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
US7777017B2 (en) Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
KR102549870B1 (ko) 다중 박테리아성 감염의 치료
AU2010200341A1 (en) Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines
AU2009210372B2 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2009202762B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
JP2019089801A (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
US7169903B2 (en) Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
AU2002365440A1 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
HK1197654B (en) Compositions and methods related to antibodies to staphylococcal protein a
AU2012254925A1 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090915